Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study

医学 嗜睡 不利影响 麻醉 入射(几何) 内科学 皮肤病科 光学 物理
作者
Tian Qian,Shifei Li,Qiquan Chen,Daojun Zhang,Zhiqiang Song,Fei Hao
出处
期刊:Dermatologic Therapy [Wiley]
卷期号:35 (5): e15386-e15386 被引量:4
标识
DOI:10.1111/dth.15386
摘要

The second-generation antihistamines at licensed doses are first-line treatment in urticaria and up-dosing is recommended as second-line treatment. To assess the efficacy and safety of escalated doses of ebastine in patients with chronic urticaria (CU), we designed this study. Recruited patients with CU were treated with increasing doses of ebstine. Treatment started at the daily dose of 10 mg. The symptom is assessed weekly, and if there is no significant improvement, the dose is increased from 10 mg to 20 mg, and if still no significant improvement, up to 40 mg. Pruritus, number, diameter, duration and frequency of wheals, and adverse reactions were assessed. One hundred and forty (76.50%) patients achieved marked effect with ebastine 10 mg/day, 27 (14.75%) patients with ebastine 20 mg/day and 13 (7.10%) patients with ebastine 40 mg/day, while 3(1.64%) patients did not get marked effect. There was no significant difference of effect between factitious urticaria, CSU, cholinergic urticaria and CSU with factitious urticaria in different dose (all p > 0.05). Common adverse reactions of ebstine treatment, included dry mouth, somnolence, tiredness and headache, were mild or moderate. There was no significant difference between the degree score of dry mouth with different doses of ebastine, and the same to somnolence, tiredness and headache (all p > 0.05). Doses escalation of ebastine should be effective in treatment of factitious urticaria, CSU and cholinergic urticaria with poorly treated by standard of double doses. Increasing ebastine dose did not increase the incidence of adverse reactions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哭哭完成签到 ,获得积分10
刚刚
nan发布了新的文献求助10
2秒前
优秀含之完成签到,获得积分20
2秒前
比奇堡完成签到,获得积分10
3秒前
4秒前
111发布了新的文献求助10
4秒前
佩楠发布了新的文献求助10
4秒前
6秒前
6秒前
6秒前
7秒前
8秒前
春衫发布了新的文献求助10
10秒前
^O^发布了新的文献求助30
10秒前
11秒前
12秒前
symptom发布了新的文献求助10
12秒前
顺利发布了新的文献求助10
12秒前
nan完成签到,获得积分10
14秒前
大佬完成签到,获得积分10
15秒前
15秒前
16秒前
16秒前
共享精神的应助被云隐采纳,获得10
17秒前
^O^完成签到,获得积分10
17秒前
Aegleseeker完成签到,获得积分10
18秒前
咻咻完成签到,获得积分10
19秒前
我我我发布了新的文献求助10
19秒前
依然完成签到,获得积分10
20秒前
20秒前
qzh006完成签到,获得积分10
20秒前
20秒前
小蘑菇的应助被geat采纳,获得10
20秒前
淡然雅寒完成签到 ,获得积分10
21秒前
21秒前
烟花的应助被暴龙战士采纳,获得10
21秒前
春桑早点睡完成签到,获得积分10
22秒前
桐桐的应助被墨洋采纳,获得10
22秒前
22秒前
MMLi发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193514
求助须知:如何正确求助?哪些是违规求助? 9579686
关于积分的说明 21866883
捐赠科研通 7793152
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484176